Iptacopan + Placebo + Rituximab
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Trial Timeline
Aug 5, 2024 → Dec 30, 2026
NCT ID
NCT06388941About Iptacopan + Placebo + Rituximab
Iptacopan + Placebo + Rituximab is a phase 2 stage product being developed by Novartis for Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis. The current trial status is active. This product is registered under clinical trial identifier NCT06388941. Target conditions include Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis.
What happened to similar drugs?
0 of 1 similar drugs in Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06388941 | Phase 2 | Active |
Competing Products
5 competing products in Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rituximab + Azathioprine | Roche | Phase 3 | 40 |
| CCX168 | Amgen | Phase 1 | 29 |
| CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin | Amgen | Phase 1 | 29 |
| CCX168 + Placebo | Amgen | Phase 1 | 29 |
| [14C]CCX168 | Amgen | Phase 1 | 29 |